The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke

Neurology

Volumn 58, Issue 1, 2002, Pages 133-135

  Van der Worp, H B ^a   Kappelle, L J ^a   Algra, A ^a   Bar P R ^a   Orgogozo, J M ^b   Ringelstein, E B ^c   Bath, P M W ^d   Van Gijn, J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HÔPITAL PELLEGRIN   (France)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TIRILAZAD;

ADULT; AGED; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE CEREBRAL ARTERY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037039233     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.1.133     Document Type: Article

References (9)

1. 21-aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils
2. Tirilazad mesylate in acute ischemic stroke. A systematic review
3. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials
4. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography
5. Measurements of acute cerebral infarction: Lesion size by computed tomography
6. Reproducibility of measurements of cerebral infarct volume on CT scans
7. Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation
8. Effect of age and gender on tirilazad pharmacokinetics in humans
9. Randomized, double-blind vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand